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ABSTRACT
Benznidazole, the primary drug used in Chagas’ disease treatment, has known side effects, 
which may limit its widespread use. Its low solubility could negatively interfere in the 
bioavailability, even accentuating the toxic effects. Cocrystals have been extensively used to 
modify and optimize physicochemical properties, but, as single-component raw materials, they 
are susceptible to the phenomenon of polymorphism. In this work, we report a trimorphic 
cocrystal containing a 1:1 ratio of benznidazole and salicylic acid. The crystalline structures of 
three polymorphs were elucidated by single-crystal X-ray diffraction. Moreover, several 
isostructural solvates were also synthesized and analyzed. The same carboxylic acid-imidazole 
supramolecular heterosynthon is present in the four forms, but the main structural feature is an 
extended column based on amide-amide hydrogen bonds. Based on the crystalline structures, 
the trimorphic system was classified as conformational and packing polymorphism. 
Furthermore, the dissolution profiles of the stable forms were determined and shown a 
significant solubility improvement over the raw material. 
Keywords: benznidazole, cocrystal, polymorphism, solvate, dissolution
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Pharmaceutical cocrystals have proven to be an efficient method to produce new solid 
forms of biologically active molecules and to optimize the physicochemical properties of drug 
substances. They are typically comprised of one or more active pharmaceutical ingredient(s) 
(API) and, at least, one pharmaceutically acceptable agent (coformer) in a stoichiometric ratio. 
Coformers typically interact via hydrogen bonds yielding novel crystalline solids 1-4.  As 
pharmaceutical cocrystals have the potential to generate improved drug substances and can be 
valuable from an intellectual property perspective, extensive work concerning their 
identification and properties characterization is required from a regulatory point of view 5, 6. 
Supramolecular synthons control the supramolecular arrangement of APIs and 
coformers in the crystalline structure. Thus, successful strategies based on synthons are 
routinely used for a priori design of cocrystals 7-9. However, the polymorphism phenomenon 
in cocrystals is far less understood, with only a few systematic studies dedicated to 
investigating this property 2, 4, 10, 11. Aitipamula et al. 11 and Duggirala et al. 12 have concluded 
that polymorphism in cocrystals is the result of serendipity even that there is an akin percentage 
of polymorphs in crystals that contain multi- or single- component solids. Thus, a survey in the 
Cambridge Structural Database (CSD) shows that the polymorphism incidence in single 
component forms (37 + 1%) is equivalent to the one of cocrystals (36 + 4%). These results 
refer to dimorphic systems, whereas cases of trimorphic systems are rare 2, 13, 14. It is important 
to note that polymorph screening methods are likely to be more challenging to apply to 
cocrystals than single component solids. This is because the mismatch between API and 
coformer solubilities can lead to mixtures of crystal types and reduce the number of solvents 
and methods capable of isolating them 11, 15.
A review paper on polymorphic cocrystals classifies dimorphs into different classes: 
synthon polymorphism, conformational polymorphism, packing polymorphism, and 
tautomeric polymorphism 14. These classes are not exclusive since a given system could 
present, to some extent, a coexistence of more than one of them. Furthermore, a search for 
binary cocrystals using the CSD conducted by Mnguni and coworkers 16 produced 2925 hits, 
of which 400 possessed at least one API and were identified as pharmaceutical cocrystals. 
Polymorphism was observed in 56 pharmaceutical cocrystals. The article found that the API 
with the higher number of polymorphic cocrystals was caffeine and, in general, caffeine 
cocrystals presented one or more of the packing, conformational, or synthon polymorphism 
types.
In synthon polymorphism, the primary synthons determining the crystal packing in the 
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polymorphic forms are different. It is a less common case because suitable molecules should 
have several binding sites capable of giving rise to the supramolecular packing characteristic 
of a cocrystal 17-19. On the other hand, conformational polymorphism is the most common kind 
20.  The key feature to distinguish these polymorphs arises in the flexibility of the constituent 
molecules, which originates from non-overlapping molecular conformations. Zaworotko and 
coworkers suggested that 92% of cocrystal polymorphs were the result of conformational 
flexibility or structural changes in the overall packing 21, 22. Packing polymorphs differ in the 
long-range arrangement of the molecules, which is more evident in the case of rigid molecules 
or those with little conformational flexibility. The fourth polymorphic cocrystal class includes 
the tautomeric polymorphs. Tautomeric forms are generally hard to detect; in consequence, 
this kind of polymorphism is rarely described in the cocrystal literature. However, when 
different crystal structures are associated with different tautomers, the system can be defined 
as exhibiting tautomeric polymorphism. Note that this group could be restricted to isomers that 
interconvert in solution or the melt because they are considered to be the same chemical 
compound 21-24. 
In this contribution, we address the polymorphism in cocrystals of benznidazole (BZN). 
The primary therapeutic use of this drug is in the treatment of Chagas disease (CD) or American 
trypanosomiasis, which belongs to the group of the 17 Tropical Neglected Diseases, according 
to the World Health Organization classification 25-27. It has been estimated that more than 7 
million people in the world are infected with Trypanosoma cruzi, the parasite that causes CD 
26. CD is an endemic disease in Latin America, which reached North America, Europe, Japan, 
New Zealand, and Australia due to immigration 25-27. Only two drugs were developed to act 
against T. cruzi in the last 40 years, BZN (LAFEPE and Abarax / ELEA) and nifurtimox 
(LAMPIT / Bayer). Comparing both, BZN causes less severe side effects. CD has two clinical 
phases, the acute phase, in which the BZN is effective, and the chronic phase, for which the 
response to treatment is much lower, and adverse effects are typically observed. At this stage, 
approximately 40% of patients develop potentially lethal conditions, such as cardiomyopathy 
and digestive or cardiodigestive symptoms 28-30. 
Polymorphism of BZN was described by Honorato et al. (2014) after two new forms 
were obtained by crystallization from the melt. BZN, Figure 1, is a nitroheterocyclic derivative, 
which exhibits low solubility and considerable toxicity 29. These characteristics have motivated 
research targeting the solubility optimization of BZN using new formulation strategies 31. 
Several methodologies have been applied to address the low solubility of BZN, including 
micronization by solvent change precipitation, solid dispersion, and inclusion complexes with 
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cyclodextrins 31-36. In general, these approaches were successful in improving the BZN 
solubility but require complex synthesis procedures. Thus, it would be preferable a new 
formulation based on crystalline forms suitable for the low-cost production of the tablets 
required for the governmental healthcare programs. This objective could be achieved using a 
crystal engineering strategy to improve the pharmaceutically relevant physicochemical 
properties of BZN. However, to the best of our knowledge, cocrystals of BZN have not been 
reported in the literature. Thus, this work presents a novel cocrystal of BZN with salicylic acid 
(SAL), BZNSAL. Three polymorphs of this cocrystal were identified, and the corresponding 
crystalline structures determined, being a rare case of a trimorphic cocrystal. A procedure to 
scale up the cocrystal production was developed, giving also rise to a series of isostructural 
solvates. Thermal analysis and X-ray powder diffraction were applied to characterize the new 
solid forms. A partial stability test was performed, and the dissolution profiles of the stable 
forms were measured and compared with the one of pure BZN.
Figure 1: Chemical structure of benznidazole (left) and salicylic acid (right)
2. MATERIALS AND METHODS
2.1. Materials 
Benznidazole was kindly donated by Laboratório Farmacêutico do Estado de 
Pernambuco (LAFEPE). Salicylic acid and all solvents were purchased from Sigma-Aldrich 
and used without further purification. Calculated X-ray powder diffractogram generated from 
the previously reported room temperature crystalline structure of BZN 37 matched that of the 
as-received sample. 
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-BZNSAL was produced by grinding and dissolving equimolecular quantities of BZN 
(0.260 g) and SAL (0.138 g) with 0.5 mL of acetonitrile in 4 mL ethyl acetate at 80 oC. The 
solution was stirred for 60 min and cooled down to room temperature over 30 minutes. Crystals 
have grown during the solvent evaporation of the resulting solution. This polymorph was only 
stable within the mother-liquor. 
β-BZNSAL was obtained by dissolving the raw materials in 3 mL chloroform and 
acetonitrile in a 1:1 ratio at 65 oC. The solution was left at 65 oC to evaporate until crystals 
appeared. High-quality crystals were obtained by grinding the sample and recrystallizing in 
chloroform. 
-BZNSAL was grown by evaporation of a chloroform solution of -BZNSAL 
previously ground with a drop of chloroform. 
The solvent assisted method was also applied to scale-up the production of the 
BZNSAL  cocrystal to perform a physicochemical characterization. The solvent assisted 
grinding  (chloroform, dioxane, or ethanol) of BZN and SAL in a 1:1 stoichiometry during 30 
minutes allowed the production of -BZNSAL. Unfortunately, it was not possible to produce 
enough amount of polymorphs  and  to carry out a detailed solid-state characterization. 
Multiple isostructural solvates, S-BZNSAL, were also obtained using selected solvents 
(water, methanol, acetonitrile, ethyl acetate, or dichlorobenzene). This powder was used as 
seeds to get crystals by slow evaporation in the same solvent. 
2.3. X-ray Powder Diffraction (XRPD)
XRPD patterns were obtained using a PANalytical EMPYREAN diffractometer system 
using Bragg-Brentano geometry and Cu Kα radiation. Room temperature scans were performed 
on a spinning silicon sample holder. The voltage and electric current applied were 40 kV and 
40 mA, respectively. The opening slit used for the incident beam on the sample was 0.6 mm. 
The patterns were recorded in the 2θ range from 5° to 40° in continuous scan mode, with a rate 
of 2 deg min-1. 
2.4.   Single Crystal X-ray Structure Determination
X-ray diffraction data collection (ϕ scans and ω scans with κ offsets) was performed on 
a Bruker-AXS SMART-APEXII-CCD diffractometer using graphite–monochromated CuKα 
radiation (1.54178 Å).  Intensity data were collected at 100K. The software Saint v8.34A 38 
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was applied for acquisition, indexing, integration, and scaling of Bragg reflections. The final 
cell parameters were obtained using all reflections.  The structure was solved with ShelXT 39 
using Direct Methods and refined with ShelXL 40 using Least Squares minimization under the 
Olex2 graphical interface 41.
Hydrogen atoms were stereochemically positioned and refined with fixed individual 
displacement parameters [Uiso(H) = 1.2Ueq or 1.5Ueq] according to the riding model (C–H 
bond lengths of 0.97 Å and 0.96 Å, for methylene and methyl groups, respectively), except for 
the O-H hydrogen atoms, which were located via difference Fourier map inspection and refined 
with fixed isotropic thermal parameters (Uiso(H) = 1.5Ueq(O)). The programs MERCURY 
(version 4.3) 42 and ORTEP–3 43 were used to prepare the crystallographic information file 
(CIF) and illustrations for publication. The CIFs of the polymorphs of BZNSAL were deposited 
in the Cambridge Structural Database under the following codes: 1563944 (), 1563945 (), 
1563946 (), and 1994297 (acetonitrile solvate).
2.5. Thermal analysis 
Thermogravimetric analysis (TG) and Differential Scanning Calorimetric (DSC) curves 
were obtained simultaneously using an STA 449 Jupiter system (Netzsch, Germany). 
Measurements were taken from room temperature up to 300 °C using a heating rate of 5 K.min-1 
and a sealed aluminum crucible with pierced lids containing 5 mg of sample. The sensors and 
the crucibles were under a constant flow of nitrogen (70 mL. min-1) during the experiment.
2.6. Dissolution profiles
The calibration curve was produced using a solution with a known concentration of 
BZN. From this solution, aliquots of 50, 100, 150, 200, and 250 μL were withdrawn and then 
diluted with a solution of ethanol and water (1/v:1/v). The same solution was used as blank for 
UV/Vis measurements, which were recorded between 200 and 400 nm on a Specord 250 
(Analytic Jena). The calibration curve was calculated considering a wavelength with good 
absorbance avoiding interference from the coformer (340 nm). Solubility studies were 
conducted suspending 10 mg of each solid form in 20 mL of water, which was kept stirring 
with a magnetic stir bar at room temperature. Aliquots were drawn at regular time intervals (5, 
10, 15, 30, 45, 60, and 120 min) and filtered using 0.45 μm nylon filters. The filtrates were 
immediately diluted appropriately with a mix of water and ethanol. The concentration was 
calculated using the previously determined calibration curve by recording the UV–Vis 
absorption at 340 nm. The solubility measurements were done in triplicates.
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3. RESULTS AND DISCUSSION
Three polymorphs of the BZN-SAL cocrystals were obtained, and their corresponding 
crystal structures determined. These polymorphs were hereafter referred to as α-, β- and γ-
BZNSAL. This specific labeling was based on stability considerations. As will be shown, -
BZNSAL is the most stable polymorphs. The remaining polymorphs were classified following 
the Burger and Ramberger density rule 44, 45, being -BZNSAL, the one with higher density, 
considered more stable than -BZNSAL. Also, solvated cocrystals were produced by solvent 
assisted grinding using acetonitrile, methanol, dichlorobenzene, water/methanol (1:2). For 
structure evaluation and comparison with the polymorphs, the crystalline structure of the 
acetonitrile cocrystal solvate (S-BZNSAL) was determined. 
Table 1: Crystallographic parameters for α-, -, γ- and S-BZNSAL.
α-BZNSAL -BZNSAL γ-BZNSAL S-BZNSAL
Empirical formula C19H18N4O6 C19H18N4O6 C19H18N4O6 C19H18N4O6·1.1(C2NH3)











Temperature (K) 100 100 100 100












α, β, γ (°) 90, 98.658(1), 90 90, 90, 90 90, 90, 90 90, 97.741(7), 90
V (Å3) 1868.19(11) 3711.09(16) 1895.95(7) 2014.0(4)
Z 4 8 4 4
Density (g cm-3) 1.416 1.426 1.396 1.458
Radiation type Cu Kα Cu Kα Cu Kα Mo Kα
µ (mm−1) 0.91 0.91 0.89 0.11
No. of measured, 
independent and
observed reflections
8106, 3346, 3264 15950, 2671, 2269 13715, 3215, 3139 48359, 4614, 3252
Rint 0.023 0.070 0.033 0.078
R[F2 > 2σ(F2)], 
wR(F2), S
0.026, 0.065, 1.08 0.041, 0.098, 1.11 0.027, 0.068, 1.08 0.068, 0.197, 1.03
Δρmax, Δρmin (e Å−3) 0.17, −0.16 0.18, −0.25 0.17, −0.23 0.79, −0.41
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The relevant crystallographic data are displayed in Table 1, crystals of α-, γ-, and S-
BZNSAL were observed to be colorless and displaying Z=4, whereas β formed yellowish 
crystals with 8 molecules per unit cell. All structures exhibit  Z’=1, as illustrated in Figure 2, 
which presents the corresponding asymmetric units. A comparison of the XRPD patterns of the 
α, β, and γ forms suggests a unique crystal packing associated with each form. The 
experimental XRPD patterns of α-BZNSAL and γ-BZNSAL exhibit good agreement with the 
calculated from the single crystal data (Figure S1). Small crystals of the β-BZNSAL polymorph 
were obtained by serendipity. Several attempts to produce a larger amount of sample were 
unsuccessful and was not possible to record the experimental XRPD pattern. At this point, it is 
also important to emphasize that γ-BZNSAL was also unstable. Single-crystal and powder 
measurements were performed in the mother-liquor because, during the drying, γ-BZNSAL 
transforms into the solvated form, as shown in Figure S2.
The three polymorphs and the solvates of BZNSAL crystallize with 1:1 stoichiometry. 
Interestingly, the O1’-H1’···N3 supramolecular heterosynthon formed between the hydroxyl 
moiety of SAL and the imidazole of BZN is present in each form, with only slight variation in 
hydrogen bond distances (Table 2). The weak C11-H11···O2’ interaction aligned API and 
coformer, forming a supramolecular dimer based on the D22(7) graph-set motif 46, 47. The 
imidazole···carboxylic supramolecular heterosynthon interaction was characteristic of all 
polymorphs and was observed in several multi-component forms leading to the formation of 
salts and cocrystals 48-51. A search in the CSD for crystalline structures having an imidazole 
group bonded to the hydroxyl group of a carboxylic acid produced 7998 hits, but only 0.57% 
resulted in cocrystals. Additional support for cocrystal formation in the BZN-SAL system, as 
opposed to the salt formation, is provided by analyzing the C-O bond distances of the 
carboxylic acid group of SAL 23, 52, 53. In the BZN-SAL system, the C-O distances of each 
carboxylic acid group were indicative of a protonated acid (~1.23 Å and ~1.32 Å, ΔDC–O~ 0.08 
Å) with little deviation among all the forms. These values were in excellent agreement with 
those expected for a cocrystal, since in salts ΔDC–O is typically < 0.03. Thus, all the structures 
of the BZNSAL system can be classified as cocrystals. 
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Table 2: Geometric parameters of the hydrogen bonds in the BZNSAL cocrystal forms.
Interaction D-H(Å) D...A(Å) H...A(Å) D-H...A(º) Symmetry code
N1-H1···O1 0.88 2.869(2) 2.02 161 x,1+y,z
O1’-H1’···N3 0.84 2.726(2) 1.89 171
O3’-H3’···O2’ 0.84 2.577(2) 1.84 146 intramolecular
C5’-H5’···O2’ 0.95 3.219(3) 2.53 129 x,-y,-1/2+z
C5’-H5’···O3’ 0.95 3.227(3) 2.46 137 x,-1-y,-1/2+z
C9-H9A···O2 0.99 2.873(3) 2.31 115 intramolecular
α-BZNSAL
C9-H9B···O3 0.99 3.377(3) 2.46 153 x,2-y,1/2+z
C11-H11···O2’ 0.95 3.112(3) 2.60 114
N1-H1···O1 0.88 2.918(2) 2.08 159 1/2-x,-1/2+y,z
O1’-H1’···N3 0.84 2.714(2) 1.88 175
O3’-H3’···O2’ 0.84 2.598(2) 1.86 146 intramolecular
C5-H5···O3’ 0.95 3.179(2) 2.49 129 1/2+x,-1+y,1/2-z
β-BZNSAL
C9-H9B···O2 0.99 2.815(2) 2.41 104 intramolecular
N1-H1···O1 0.88 2.847(2) 1.99 164 x,-1+y,-z
O1’-H1’···N3 0.84 2.713(2) 1.88 170
O3’-H3’···O2’ 0.84 2.575(2) 1.84 145 intramolecular
C5’-H5’···O2’ 0.95 3.224(42) 2.53 130 1/2+x,5/2-y,z
C5’-H5’···O3’ 0.95 3.211(2) 2.45 137 1/2+x,7/2-y,z
C7-H7A···O1 0.99 2.834(3) 2.50 100 intramolecular
γ-BZNSAL
C9-H9B···O1 0.99 3.211(2) 2.52 126 x,-1+y,-z
N1-H1···O1 0.88 2.893(3) 2.04 163 x,1+y,z
O1’-H1’···N3 0.84 2.701(3) 1.86 175 1/2-x,3/2+y,3/2-z
O3’-H3’···O2’ 0.84 2.573(3) 1.84 145 intramolecular
C4-H4···O2 0.95 3.357(4) 2.60 137 1-x,3-y,1-z
C9-H9B···O1 0.99 3.164(4) 2.59 117 x,1+y,z
C9-H9B···O2 0.99 2.795(3) 2.42 101 intramolecular
S-BZNSAL
C12-H12···O2’ 0.95 3.004(3) 2.41 120 x,-1+y,z
C12-H12···O3’ 0.95 3.303(4) 2.48 145
The SAL molecular conformation was the same in the four forms, supported by an O3’-
H3’···O2’ intramolecular hydrogen bond, and forming an S(6) graph-set motif (Table 2). 
Considering the relative orientation of the two molecules in the asymmetric unit, the imidazole 
ring of BZN is nearly coplanar with the SAL molecule in the case of the α, γ, and S forms, and 
slightly twisted in β, with angles between the ring planes of 2.60°, 4.68°, 1.89°, and 21.08°, 
respectively (Figure 3a). The main difference between the three polymorphs and the solvate 
lies in the conformation of the BZN molecule. Figure 3b shows an overlay of the BZN 
conformation in the α, β, γ, and S forms compared with BZN. Table 3 lists the dihedral angles. 
By aligning the amide groups, phenyl rings exhibit a similar orientation with slight variations 
due to changes in the C1-C7-N1 angle (from 110.05 to 110.44°). Examination of the 
nitroimidazole group reveals the C9-H9···O2 intramolecular hydrogen bond favors a trans 
orientation of the nitro group and the phenyl ring in all the structures but the α form, where 
they are in the cis conformation. Thus, considering these conformational differences, BZNSAL 
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forms could be classified as conformational polymorphism. However, this is not the only 
polymorphic class which could be used to describe the BZNSAL system. 
Figure 2: Asymmetric unit of α-BZNSAL, β-BZNSAL, γ-BZNSAL, and S-BZNSAL.  
Disordered acetonitrile molecules in S-BZNSAL are presented in purplish colors. 
Table 3: Characteristic torsions (o) and angle (o) between the planes in the imidazole and 
phenyl rings of the BZN molecule in α, β, and γ-BZNSAL forms  20.
C2C1C7N1 C1C7N1C8 C7N1C8C9 N1C8C9N2 C8C9N2C10 Angle 
BZN 64.50 -167.46 176.40 163.94 -77.34 20.25
α-BZNSAL 61.90 -150.54 176.35 -171.32 -82.49 16.36
β-BZNSAL 65.49 -150.59 176.51 -178.79 -68.74 3.39
γ-BZNSAL 58.63 -140.00 176.36 -158.23 56.57 36.83
S-BZNSAL 97.77 170.13 174.91 169.66 -64.98 14.66
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Figure 3: (a) Relative orientation of the SAL and BZN molecules in the polymorphs and 
solvate of the BZNSAL cocrystal. (b) Overlay of the molecular conformation of BZN in α-
BZNSAL (orange), β-BZNSAL (blue), γ-BZNSAL (red), S-BZNSAL (purple), and pure BZN 
(green).
The second strongest intermolecular hydrogen bond is N1-H1···O1, which results in 
infinite H-bonded chains connecting the amide groups of BZN molecules (Figure 4). 
Interestingly, this intermolecular interaction, also present in pure BZN, is preserved in the 
BZNSAL polymorphs and solvated forms. In most of the reported structures, BZN molecules 
are similarly oriented along the chains, with the nitro groups facing the same direction. That is 
the case of α, γ, and S forms. Conversely, the form β asymmetric unit is approximately bisected 
by a glide plane along the b-axis, and the nitroimidazole and phenyl groups are alternated in 
opposite directions along the chain.  This organization is accompanied by the SAL molecule, 
which is flipped on successive synthons of the chain. 
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Figure 4: Infinite columns determined by the N1-H1···O1 hydrogen bond found in the 
polymorphs and solvated BZNSAL cocrystal.
Figure 5 shows the projection of the crystalline structures of the BZNSAL forms 
perpendicular to the amide-amide chains. The distinctive infinite columns are the main 
supramolecular structures defining the crystal packing of the new BZNSAL forms. This 
description can also be applied to the crystalline structure of pure BZN since in the plane 
perpendicular to the infinite columns, rows of BZN molecules can be identified along the [101] 
direction (Figure 5). The “asymmetric unit” of this 2D H-bonded network is composed of two 
infinite columns with perpendicular BZN molecules. Considering first the BZNSAL 
polymorphs, it is possible to assume that the cocrystal is the consequence of the substitution of 
one of BZN columns by one of the coformer. SAL columns are not stabilized by intracolumn 
interaction, like the BZN ones. In α and γ polymorphs, bifurcated C5’-H5’···O2’ and C5’-
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H5’···O3’ non-classical hydrogen bonds link neighbor SAL columns, whereas, in the β form, 
SAL molecules follow the BZN columns without further interactions. In -BZN-SAL columns, 
the supramolecular unit propagates along the c-direction due to a 21 screw axis, being columns 
organized in successive layers with opposite orientations. A converse packing is observed in 
the β-polymorph; i.e., the asymmetric unit is aligned following the [001] direction but switched 
over on the [100] one. Finally, molecules are oriented similarly in both directions on the ac-
plane in  form. Comparing the differences in the arrangement of the infinite amide-amide 
columns, it is also possible to classify the polymorphs of the BZNSAL cocrystal as packing 
polymorphism.
Figure 5: Projection of the crystal packing of BZN (bc-plane),  BZNSAL polymorphs (ac-
plane), and solvate (ac-plane). Lattice parameters are color-coded (red) a, (green) b, and (blue) 
c.
Concluding the discussion on the BZNSAL polymorphism, a Hirshfeld surface and 
fingerprints analysis was performed using the Crystal Explorer software 54. The Hirshfeld 
surface is a very reliable tool when describing packing patterns, allowing to differentiate 
polymorphs 55-57. This approach is currently used for the rapid interpretation of structural 
features since 2D fingerprint plots can be readily constructed from these potential maps. 
Intermolecular interactions present in the crystal lattice are used to construct the fingerprint 
graphics, by plotting de (external distance, defined as the distance between the calculated 
Hirshfeld surface and the nearest atom of an adjacent molecule within the crystal) versus di 
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(internal distance, defined as the shortest separation from the calculated Hirshfeld surface to 
an atom nucleus of the molecule inputted for surface calculation). The distance de is associated 
with short intermolecular interactions. Relationships between crystal packing patterns and 
molecular geometry are understood by analyzing parameters present in Hirshfeld fingerprint 
plots. The di values provide information on atomic and ionic radii 58. 
Figure 6: dnorm Hirshfeld surface α-BZNSAL (a.1), β-BZNSAL (b.1), and γ-BZNSAL (c.1). 
Shape index surface plots for α-BZNSAL (a.2), β-BZNSAL (b.2), and γ-BZNSAL (c.2).
The NH∙∙∙O interactions in the BZN molecules are visualized as bright red spots 
(negative electrostatic potential, H-bond acceptors) on the Hirshfeld surfaces mapped over 
dnorm (Figure 6 a.1-c.1), indicating the close contact interaction. The positive electrostatic 
potential (blue region) over the surface indicates a hydrogen donor. Furthermore, 
intermolecular contacts were evidenced in the fingerprint plots (Figure 7). H∙∙∙H intermolecular 
contacts are associated with the large surface in the middle of the scattered points (). The 
N∙∙∙H contacts define the left spike of SAL structure (), while the two central spikes 
associated with the BZN molecules are related to the NH∙∙∙O contacts (). These spikes are 
also observed in the fingerprint plot of pure BZN since this hydrogen bond defines the infinite 
columns that characterize the structures involving BZN. Another interesting feature can be 
identified in the Hirshfled surfaces mapped with the shape index. Large red depressions () 
are observed over the phenyl rings in the three polymorphs (Figure 6 a.2-c.2), which are 
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characteristic of CH∙∙∙ interactions. There are similar depressions over the imidazole rings on 
the opposite side of the surface. CH∙∙∙ interactions are also evidenced in the fingerprint plots 
as the symmetric small “wings” (). Thus, the amide-amide hydrogen bonds stack the BZN 
molecules forming chains, but the alignment of these molecules is defined by the methyl groups 
through the C7H∙∙∙(imidazole) and C9H∙∙∙(phenyl) interactions. The analysis of the 
fingerprint plots clearly shows that all the polymorphs retain the same primary intermolecular 
interaction ruling out the possibility of synthon polymorphism. 
Figure 7: Comparison of the fingerprint plots of SAL and BZN for each cocrystal polymorph 
and pure BZN. The di is the distance from the Hirshfeld surface to the nearest atom interior to 
the surface, and de is the distance from the surface to the nearest atom exterior to the surface.
The solvated form shares most of the main structural features of the BZNSAL 
polymorphs, that is,  the same drug-coformer synthon and the amide-amide columns. However, 
the distinctive supramolecular packing of S-BZNSAL needs to be discussed in detail. Figure 5 
shows that the BZN columns are not arranged in layers like the polymorphs but as pairs 
intercalated with the extended cavities where the solvent molecules are placed. BZN molecules 
have complementary orientations with the nitro groups facing the phenyl groups, which favors 
the new hydrogen bond C4-H4···O2 forming BZN dimmers and stabilizing this crystal 
packing. This particular organization of the amide-amide columns leaves two solvents 
accessible voids located approximately in the middle of the a and c axes at (0.500,0.038,0.000) 
and (0.000,-0.098,0.500), respectively. Within these cavities, no relevant interactions hold the 
solvent molecules at fixed positions. In the case of the acetonitrile solvate used as a model to 
discuss the S-BZNSAL structure, five disordered partially occupied molecules were necessary 
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to obtain a reliable model. These molecules seem to be organized around two sites within the 
asymmetric unit, but the expansion of the lattice along the b axis shows that they are randomly 
distributed, filling the channels between the BZN columns. Two approaches were applied to 
determine the solvent stoichiometry. First, the sum of the refined occupation of the acetonitrile 
molecules included in the model gives a concentration of 1.15 solvent molecules in the 
structure, but there are still some residual charges which were not adequately modeled. On the 
other hand, the SQUEEZE method implemented in PLATON 59 was used to estimate the 
presence of 90 electrons per unit cell inside the voids, giving a stoichiometry of 1.41 
acetonitrile molecules per asymmetric unit. Both methods lead to similar values and suggest 
that S-BZNSAL is a non-stoichiometric solvate. 
Low-quality crystals were obtained using other solvents, but the solved crystalline 
structure did not exhibit appreciable differences with the acetonitrile solvate. For example, the 
lattice parameters of several solvates show variations lower than 1%. The isostructural 
character of the BZNSAL solvates is evidenced in the comparison of the XRPD patterns of 
several samples prepared by grinding with selected solvents shown in Figure S3. These patterns 
just differ in the relative intensities of some peaks, which could be ascribed to the presence of 
different non-stoichiometric solvents inside the channels 60, 61. The different solvates can also 
be compared using thermal analysis methods. The mass loss associated with the solvent release 
is not well defined in the TG curves because the relative concentration of the solvent seems to 
be small. TG curves of both α- and S-BZNSAL are dominated by two events around 159 and 
200 oC (Figure S4), which are respectively related to the boiling of SAL and decomposition of 
BZN 37. Instead, DSC measurements evidence the solvent loss as an endothermic peak in the 
range of 110 to 140 oC, whose temperature depends on the solvent identity, as seen in the top 
inset of Figure 8. The solvent release peak is followed by a larger and asymmetric one 
associated with the melting of the desolvated form. The onset of this peak also depends on the 
solvent and ranges between 145 and 155 oC. 
The methanol solvate was heated up to 140 oC and cooled down to room temperature 
to investigate the desolvation process. The XRPD patterns before and after this process are 
shown in the bottom inset of Figure 8. The pattern obtained after the desolvation agrees very 
well with the one of α-BZNSAL, showing that the solvate converts into this form on heating. 
The onset of the melting point of α-BZNSAL is approximately 155 oC. The same DSC curve 
is observed in the samples produced using chloroform since the grinding with this solvent 
systematically gives α-BZNSAL, being the method used to scale up this polymorph. 
Unfortunately, it was not possible to find an alternative strategy to obtain an amount of the 
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other polymorphs enough to carry on a detailed physicochemical characterization. It is also 
interesting to point out that S-BZNSAL can be recovered from α-BZNSAL by grinding with 
an adequate solvent. 
Figure 8: Differential scanning calorimetry of S-BZNSAL(methanol) as prepared and after 
heating to 140 oC. The top inset shows the DSC curves of solvates prepared with different 
solvents. The bottom inset presents the XRPD patterns of S-BZNSAL(methanol) before and 
after the heating process. 
A partial stability test of α-BZNSAL and S-BZNSA was carried out for two months. 
The samples were left in open jars in a temperature- and humidity-controlled chamber (40 °C 
and 75% relative humidity) and periodically evaluated by XRPD. At least during the 
investigated period, both compounds remained with the same crystalline structure without 
showing evidence of degradation, phase transformations, or crystallinity loss, as shown in 
Figure S5.
The usual methodology to determine the BZN solubility considers measuring the 
transmitted UV/VIS intensity at the absorption maximum 62, 63. This strategy cannot be directly 
applied to the BZNSAL cocrystal because the coformer absorption spectrum also needs to be 
considered. Figure S5 shows the absorption spectra of BZN and SAL. Notice that at the BZN 
absorption maximum, the SAL spectrum still contributes about 10% to the total absorbance. 
Due to that, the calibration curve was calculated at 340 nm, where the SAL absorption is lower 
than 1%. The calibration curve is shown in the inset of Figure S6. 
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Figure 9: Dissolution profiles in distilled water of BZN, α-BZNSAL, and S-
BZNSAL(methanol). The inset shows the XRPD patterns of the solid residues at the end of the 
assays.
Having developed a specific methodology for the BZNSAL cocrystals, it was applied 
to determine the aqueous dissolution profiles of BZN, α-BZNSAL, and S-BZNSAL (methanol) 
to asses if the cocrystallization strategy gives any physicochemical advantage over the form 
used in the formulations. Figure 9 depicted the calculated solubility as a function of time. After 
120 min, the three compounds converge to the same value 0.25(1) mg/ml, which agrees very 
well with the previously reported intrinsic water solubility of BZN 62. Despite the fact, the two 
forms of the BZNSAL cocrystal reach the saturation solubility of BZN after 120 min, each one 
exhibits a characteristic dissolution profile. BZN shows the usual continuous increase of the 
solubility up to the thermodynamic equilibrium. Rapid dissolution of α-BZNSAL was observed 
in the early phase, achieving a small supersaturation of about 10%. However, the apparent 
solubility is 50% higher than BZN during the first 5 min and, later, converges slowly to the 
saturation value. Finally, S-BZNSAL exhibits a moderate spring-parachute effect 64 with a 
supersaturation maximum around 30 min, being higher then BZN by 30-40% during the first 
45 min. As expected, the XRPD pattern of the BZN residue in the dissolution test shows no 
changes compared to the original sample (Figure 9). Furthermore, the patterns of the residues 
from - and S-BZNSAL assays were identified as the solvated cocrystal, showing that α-
BZNSAL transforms into the solvated form by slurry conversion. These results confirm that 
both the dissolution rate at early time points and the maximum dissolved concentration in 
middle time points of α- and S-BZNSAL were superior to those of BZN. Thus, both forms of 
the BZNSAL cocrystal are valuable options to improve the BZN solubility. 
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The combination of BZN and SAL by wet and solved assisted grinding and slow 
evaporation resulted in polymorphs and solvates of a new cocrystal. These forms were 
characterized by powder and single-crystal X-ray diffraction and were identified as three 
polymorphs (α, β, and γ) and a series of isostructural solvates. These structures are primarily 
sustained by O1’-H1’···N3 and N1-H1···O1 intermolecular interactions. Significant structural 
differences between the α, β, and γ forms were identified by considering torsion angles and 
hydrogen bonds. From the structural point of view, this rare trimorphic cocrystal system 
maintains the supramolecular synthon, but the overall crystal packing and torsion angles vary 
within the series. These results suggest that the BZNSAL system can be classified as exhibiting 
packing and conformational polymorphism. 
In the case of the solvated cocrystals, several solvents were able to occupy the channels 
between the drug-coformer columns defining the crystalline packing. The solvent is disordered 
inside the channels, forming a non-stoichiometric solvate. Thermal analysis confirm the 
presence of different solvents depending on the synthesis condition. Furthermore, it was 
possible to transform the solvated cocrystals into the α polymorph by heating and to recover 
the solvated form by grinding with an adequate solvent. 
A partial stability test suggests that the α polymorph and the solvate have good stability. 
Furthermore, the aqueous dissolution profiles of these forms of the BZNSAL cocrystal were 
investigated. Both cocrystal forms exhibited better dissolution rates compared to that of pure 
BZN. 
Summarizing, the α- and S- forms of the BZNSAL cocrystal were easily reproduced, 
and suitable for a scale-up process using solvent assisted grinding. Furthermore, both forms 
seem to have acceptable stability and enhanced solubility. Taking into consideration the 
improved properties of the BZNSAL cocrystal, it can be concluded that novel formulations of 
BZN based on a crystal engineering strategy are viable. 
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PXRD patterns (Figures S1-S3, S5), thermal analysis (S4) ans UV/VIS spectra as described 
in the text
Accession Codes 
CCDC 1563944-1563946 and 1994297 contain the supplementary crystallographic data for 
this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, 
or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge 
Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 
336033.
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Cocrystal polymorphs and solvates of the anti-Trypanosoma cruzi drug benznidazole 
with improved dissolution performance
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Table of Contents Graphic
Synopsis 
Three polymorphs and a series of isostructural solvates of the salicylic acid cocrystal of 
benznidazole, the primary drug used in the treatment of Chagas’ disease, were produced. This 
trimorphic system can be classified as exhibit conformational and packing polymorphism. The 
dissolution profiles of the stable forms were determined to show a significant solubility 
improvement over the raw material. 
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Figure 1: Chemical structure of benznidazole (left) and salicylic acid (right) 
223x65mm (96 x 96 DPI) 
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Figure 2: Asymmetric unit of α-BZNSAL, β-BZNSAL, γ-BZNSAL, and S-BZNSAL.  Disordered acetonitrile 
molecules in S-BZNSAL are presented in purplish colors. 
190x304mm (96 x 96 DPI) 
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Figure 3: (a) Relative orientation of the SAL and BZN molecules in the polymorphs and solvate of the 
BZNSAL cocrystal. (b) Overlay of the molecular conformation of BZN in α-BZNSAL (orange), β-BZNSAL 
(blue), γ-BZNSAL (red), S-BZNSAL (purple), and pure BZN (green). 
112x181mm (96 x 96 DPI) 
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Figure 4: Infinite columns determined by the N1-H1···O1 hydrogen bond found in the polymorphs and 
solvated BZNSAL cocrystal. 
169x305mm (96 x 96 DPI) 
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Figure 5: Projection of the crystal packing of BZN (bc-plane), BZNSAL polymorphs (ac-plane), and solvate 
(ac-plane). Lattice parameters are color-coded (red) a, (green) b, and (blue) c. 
268x199mm (96 x 96 DPI) 
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Figure 6: dnorm Hirshfeld surface α-BZNSAL (a.1), β-BZNSAL (b.1), and γ-BZNSAL (c.1). Shape index 
surface plots for α-BZNSAL (a.2), β-BZNSAL (b.2), and γ-BZNSAL (c.2). 
239x187mm (150 x 150 DPI) 
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Figure 7: Comparison of the fingerprint plots of SAL and BZN for each cocrystal polymorph and pure BZN. 
The di is the distance from the Hirshfeld surface to the nearest atom interior to the surface, and de is the 
distance from the surface to the nearest atom exterior to the surface. 
229x114mm (96 x 96 DPI) 
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Figure 8: Differential scanning calorimetry of S-BZNSAL(methanol) as prepared and after heating to 140 oC. 
The top inset shows the DSC curves of solvates prepared with different solvents. The bottom inset presents 
the XRPD patterns of S-BZNSAL(methanol) before and after the heating process. 
272x208mm (300 x 300 DPI) 
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Figure 9: Dissolution profiles in distilled water of BZN, α-BZNSAL, and S-BZNSAL(methanol). The inset 
shows the XRPD patterns of the solid residues at the end of the assays. 
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